Publication
Adalimumab and number of previous biological disease-modifying antirheumatic drugs as predictive factors for the development of immune-mediated skin lesions
| dc.contributor.author | Martins, A. | |
| dc.contributor.author | Oliveira, D. Santos | |
| dc.contributor.author | Martins, F. R. | |
| dc.contributor.author | Nicolau, R. | |
| dc.contributor.author | Pinheiro, F. Oliveira | |
| dc.contributor.author | Rato, M. | |
| dc.contributor.author | Bernardo, A. | |
| dc.contributor.author | Pimenta, S. | |
| dc.contributor.author | Bernardes, M. | |
| dc.contributor.author | Costa, L. | |
| dc.date.accessioned | 2025-03-14T10:44:43Z | |
| dc.date.available | 2025-03-14T10:44:43Z | |
| dc.date.issued | 2023-06 | |
| dc.description | European Congress of Rheumatology (EULAR) | |
| dc.description.abstract | Treatment of inflammatory rheumatic diseases has dramatically changed with the introduction of biologic disease modifying anti-rheumatic drugs (bDMARDs). However, these drugs aren’t exempt from risks and skin lesions are the most frequent adverse reactions. Among the possible adverse skin reactions, immune-mediated skin lesions (IMSL) may occur. Risk factors associated with the occurrence of IMSL in rheumatic patients under bDMARDs are poorly known and studied. | eng |
| dc.identifier.doi | 10.1136/annrheumdis-2023-eular.2061 | |
| dc.identifier.issn | 0003-4967 | |
| dc.identifier.uri | http://hdl.handle.net/10400.1/26910 | |
| dc.language.iso | eng | |
| dc.peerreviewed | yes | |
| dc.publisher | Elsevier | |
| dc.relation.hasversion | https://ard.bmj.com/content/82/Suppl_1/1408.1.info | |
| dc.relation.ispartof | Annals of the Rheumatic Diseases | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | Skin | |
| dc.subject | bDMARD | |
| dc.title | Adalimumab and number of previous biological disease-modifying antirheumatic drugs as predictive factors for the development of immune-mediated skin lesions | eng |
| dc.type | conference object | |
| dspace.entity.type | Publication | |
| oaire.citation.conferenceDate | 2023-05-31 | |
| oaire.citation.conferencePlace | Milan, ITALY | |
| oaire.citation.endPage | 1408 | |
| oaire.citation.issue | Suplemento 1 | |
| oaire.citation.startPage | 1408 | |
| oaire.citation.title | Annals of the Rheumatic Diseases | |
| oaire.citation.volume | 82 | |
| oaire.version | http://purl.org/coar/version/c_970fb48d4fbd8a85 |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- ADALIMUMAB AND NUMBER OF PREVIOUS BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AS PREDICTIVE FACTORS FOR THE DEVELOPMENT OF IMMUNE-MEDIATED SKIN LESIONS.pdf
- Size:
- 240.85 KB
- Format:
- Adobe Portable Document Format
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 3.46 KB
- Format:
- Item-specific license agreed upon to submission
- Description: